Newsroom

Videoconference and publication of annual financial results, Tuesday, June 16, 2026

May 28, 2026

Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

May 26, 2026

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults

May 21, 2026

UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year

April 29, 2026

Degroof Petercam Initiates Medincell’s Coverage with a “Buy” Recommendation

April 22, 2026

Leerink Partners Initiates Medincell’s Coverage with a “Outperform” Recommendation

April 21, 2026

EIB Waives its Right to Cash Settlement on Medincell Warrants

March 26, 2026

Medincell announces successful c. €48 million Private Placement

March 6, 2026

Medincell launches a private placement for international institutional investors

March 5, 2026

Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026

March 4, 2026

Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026

February 24, 2026

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults

February 20, 2026